|

New Anti-Mesothelioma Antibody and Biomarker Discovered

ByHolly Zink

New Anti-Mesothelioma Antibody and Biomarker Discovered Dr. Tsuji is working on discovering specific cancer antigens for malignant mesothelioma. A new study from the Gunma University of Health and Welfare shows a new anti-mesothelioma antibody for the diagnosis and treatment of mesothelioma.

The use of antibody drugs is becoming more popular in the treatment of mesothelioma. Antibody drugs are immunotherapy treatments. They recruit your body’s germ-fighting immune system to fight against mesothelioma.

One the of biggest problems with mesothelioma immunotherapy is a lack of biomarkers.

Mesothelioma is Difficult to Diagnose and Treat with Biomarkers

Mesothelioma is a rare and aggressive cancer often caused by asbestos exposure. Malignant mesothelioma is characterized by poor prognosis and short survival.

Malignant mesothelioma is considered a treatment-resistant (intractable) cancer. Clinicians and researchers often call mesothelioma an “indistinct” cancer. This is because we don’t have good cancer genetic biomarkers and it is difficult to diagnose.

Antibody drugs use anti-tumor immune activity to attack cancer cells. To work at their best, they need a strong genetic biomarker. This genetic biomarker tells the immune system which cells are mesothelioma cancer cells.

A New Anti-Mesothelioma Antibody

Dr. Tsuji is looking for a biomarker for mesothelioma that could be used to develop anti-mesothelioma immunotherapies. This biomarker will help in the diagnosis of mesothelioma. And it will help in the development of targeted treatments.

Results published in Glyco Forum report that the antibody SKM9-2 shows high sensitivity for mesothelioma. This means scientists can use SKM9-2 as a mesothelioma biomarker.

SKM9-2 antibodies are drawn to mesothelioma almost like magnets. And these cancer-seeking antibodies can be used in a few different ways.

First, clinicians introduce SKM9-2 antibodies into the body, those antibodies go to work to find mesothelioma tumor cells. Clinicians can use this technique with clinical imaging to find and diagnose mesothelioma. They can also use these antibodies to create more effective anti-cancer treatments.

SKM9-2 has not yet been established as a traditional antibody drug. Dr. Tsuji working to develop SKM9-2 as a new-generation antibody drug.

Source

Tsuji, Shoutaro. “Medical Applications of SKM9-2, an Antibody That Recognizes Glycopeptides.” Glycoforum 25 (2022): A5. https://doi.org/10.32285/glycoforum.25A5

Similar Posts

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    ByAlex Strauss

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…

  • |

    Mesothelioma Blood Test May Be Possible

    ByAlex Strauss

    An international team of researchers is studying the proteins found on the surface of cancer cells in an effort to improve mesothelioma diagnosis. The team, made up of scientists from the US, Switzerland, Italy and Chile, has just published their findings on a new kind of test to identify protein-derived mesothelioma biomarkers in blood serum. Mesothelioma is an aggressive cancer of the membranes around organs. Because the most common mesothelioma biomarker, mesothelin, is also overproduced by other kinds of cancer cells, it has only limited diagnostic value. A test to identify a set of proteins produced specifically by mesothelioma cells could greatly improve diagnostic accuracy. Led by Ferdinando Cerciello and Bernd Wollscheid of the Institute of Molecular Systems Biology in…

  • |

    Study Confirms Firefighters at Elevated Risk for Mesothelioma

    ByAlex Strauss

    A 5-year National Institute for Occupational Safety and Health (NIOSH) study of U.S. firefighters is the first to confirm what has long been suspected: Firefighters are definitely at higher risk for malignant mesothelioma. The study examined the mortality patterns and cancer incidence (including mesothelioma) among 30,000 firefighters in three major cities. The study subjects were all career firefighters who started their careers after 1950 and were followed through 2009. In order to get a diverse sample of firefighters from across the country, the study focused on firefighters from San Francisco, Chicago and Philadelphia. Comparing firefighters to a sampling of the general public, the study looked at 92 causes of death and 41 cancer incidence groupings, with a focus on 15…

  • | |

    Needle Biopsy “Simple, Safe & Accurate” for Mesothelioma

    ByAlex Strauss

    Mesothelioma researchers in China say a biopsy method that involves a single skin puncture can produce good diagnostic results for mesothelioma patients with little pain or risk. The study focused on percutaneous (through the skin) biopsy in patients who had unexplained fluid buildup or swelling in their abdomens. Abdominal distension and fluid buildup (called ascites) can be signs of peritoneal mesothelioma, a rare but aggressive cancer of the abdominal lining caused by exposure to asbestos. Peritoneal mesothelioma accounts for less than 30% of all mesothelioma cases. Because the symptoms may be vague and often develop many decades after asbestos exposure, peritoneal mesothelioma can be especially challenging to diagnose.  Misdiagnosis and under-diagnosis are not uncommon. In the newest study on percutaneous…

  • | |

    Inflammation Both “Friend and Foe” in Mesothelioma

    ByAlex Strauss

    An immune system response that causes mesothelioma symptoms such as fever, fatigue, and weight loss may also be helpful to clinicians as a way to find and treat the disease. Scientists with The Asbestos Diseases Research Institute in Sydney, Australia make that case that both systemic inflammation (throughout the body) and at the site of a tumor – has long been associated with mesothelioma and other cancers. Inflammation results when the body attempts to address the imbalances of cancer by producing more of certain immune system cells. Some inflammatory markers, such as CD+8 T-cells and C-reactive protein, have been linked to better prognosis in mesothelioma. Other inflammatory markers, such as certain macrophages and a high neutrophil-to-lymphocyte ratio, can signal the…

  • | |

    Could Statin Drugs Help Fight Mesothelioma?

    ByAlex Strauss

    A new study suggests that some of the most popular drugs used to treat high cholesterol may also help combat deadly malignant mesothelioma. That finding comes from Japanese research, published recently in the medical journal, Cancer Letters. The study found a “synergistic effect” in mesothelioma cells between two statin drugs, atorvastatin (Lipitor) and simvastatin (Zocor) and gamma tocotrienol (y-T3), a form of Vitamin E. “Statin+y-T3 combinations induced greater cell growth inhibition more than each single treatment,” write the authors in the summary of their findings. The combination of statin drugs and gamma-tocotrienol appears to work by inhibiting an important metabolic pathway inside the mesothelioma cells, making it impossible for them to synthesize or utilize certain critical molecules. When the researchers…